---
search:
  boost: 2 
---

 # Growth Hormone

This is a subcategory of Endocrine Agents.

## Formulary

### Preferred

| Preferred                 | Generic Name | Quantity | Time (Days) |
| :------------------------ | :----------- | :------: | :---------: |
| Genotropin <sup>PA</sup>  |              |          |             |
| Norditropin <sup>PA</sup> |              |          |             |

### Non-Preferred

| Non-Preferred | Generic Name | Quantity | Time (Days) |
| :------------ | :----------- | :------: | :---------: |
| Humatrope     |              |          |             |
| Nutropin      |              |          |             |
| Omnitrope     |              |          |             |
| Saizen        |              |          |             |
| Serostim      |              |          |             |
| Skytrofa      |              |          |             |
| Zomacton      |              |          |             |

## Length of Authorizations

Initial: 180 days

Subsequent: 365 days

## All Authorizations

Must be prescribed in accordance with FDA approved labeling

## Clinical PA Criteria

**Pediatric Approvals (under 18 years of age):**

- Must be treated and followed by a pediatric endocrinologist, nephrologist, clinical geneticist, endocrinologist, or gastroenterologist (or as appropriate for diagnosis)
- Must provide documentation to justify criteria being met, including height, weight, bone age (children), date and results of most current x-ray, stimulus test results, IGF-1 levels, and a growth chart (children)
- Must not being used in combination with another somatropin agent

**Adult Approvals (18 years of age or older):**

- Must be treated and following by an endocrinologist
- Must provide documentation of growth hormone deficiency by means of a negative response to an appropriate stimulation test (clonidine test is not acceptable for adults)
- Must provide documentation of baseline evaluation of the following clinical indicators: (1) insulin-like growth factor (IGF-1); (2) fasting lipid profile; (3) BUN; (4) fasting glucose; (5) electrolytic levels; (6) evaluation of any new osteoarthritis and joint pain; (7) bone density test
- Must have had other hormonal deficiencies addressed with adequate replacement therapy

## Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least **90 days** with at least **one preferred** drug
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

## Subsequent Authorization Criteria

- Must provide documentation of patientâ€™s clinical response to treatment and ongoingcsafety monitoring (i.e., height, weight gain, improved body composition) For adults: must provide documentation by endocrinologist that discontinuing agent would have a detrimental effect on body composition or other metabolic parameters

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL%20_Criteria_APPROVED.pdf#page=57)

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL_APPROVED_12.13.22.pdf#page=13)

[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf)
